Provider Briefing: Aurovela Fe 1/20 Availability in 2026

If your patients have been calling about trouble filling their Aurovela Fe 1/20 prescriptions, you're not alone. Providers across the country have seen an uptick in contraceptive access issues related to this specific generic — and the situation has persisted, in various forms, since 2022.

This article provides a concise clinical briefing on the current state of Aurovela Fe 1/20 availability, the factors driving the issue, prescribing implications, and practical tools to help your patients maintain contraceptive continuity.

Timeline of Availability Issues

The Aurovela Fe 1/20 availability problem has evolved over several years:

• 2022: Initial patient reports surfaced on social media and patient forums, with some Walgreens locations telling patients Aurovela Fe 1/20 had been "discontinued." The drug was not discontinued — Aurobindo Pharma continued manufacturing.
• 2023-2024: Availability issues became more widespread as major chain pharmacies (CVS, Walgreens, Rite Aid) made formulary changes, deprioritizing Aurovela Fe 1/20 in favor of other norethindrone acetate/ethinyl estradiol generics. CVS reportedly removed Aurovela from its preferred drug list in some markets.
• 2025-2026: The situation remains pharmacy-dependent rather than supply-dependent. Aurovela Fe 1/20 is not listed on the FDA Drug Shortage database. Aurobindo Pharma continues to manufacture and distribute the product. Availability is spotty at chain pharmacies but generally accessible through independent pharmacies and distributors.

Prescribing Implications

The intermittent availability of Aurovela Fe 1/20 has several implications for prescribers:

Contraceptive Continuity Risk

Patients who cannot fill their prescription on time may experience gaps in contraceptive coverage, increasing the risk of unintended pregnancy. This is particularly concerning for patients who have been stable on this formulation and may not realize they need to act proactively to find stock.

Patient Confusion About Generics

Many patients are uncertain whether switching between generic versions of the same formulation is safe. They may delay filling a prescription for an equivalent generic because they believe it's a "different drug." Clear patient education from the prescriber can mitigate this concern.

Prescription Writing Best Practices

To maximize fillability, consider these approaches:

• Prescribe by generic name: Write prescriptions for "norethindrone acetate/ethinyl estradiol 1 mg/20 mcg with ferrous fumarate" rather than a specific brand or generic trade name.
• Allow substitution: Ensure "substitution permitted" (or equivalent in your state) is indicated on the prescription.
• Quantity: Consider prescribing 3-month supplies where insurance allows, reducing the frequency of refill-related disruptions.

Current Availability Picture

As of early 2026, the availability landscape looks like this:

• Chain pharmacies: Inconsistent. Many CVS, Walgreens, and Rite Aid locations no longer stock Aurovela Fe 1/20 as a preferred generic. Availability varies by region and individual store.
• Independent pharmacies: Generally more accessible. Independent pharmacies can order from multiple distributors and are not bound by the same formulary restrictions as chains.
• Mail-order pharmacies: Available through several mail-order and online pharmacy services.
• Distributors: Aurovela Fe 1/20 remains available through major pharmaceutical distributors (McKesson, Cardinal Health, AmerisourceBergen). Pharmacies that want to stock it generally can.

Cost and Access Considerations

Cost should not be a significant barrier for most patients:

• Insurance: Under the ACA contraceptive mandate, most insurance plans cover oral contraceptives — including Aurovela Fe 1/20 and its equivalents — at $0 copay.
• Cash price: $27 to $49 per 28-day pack without insurance.
• Discount programs: GoodRx and SingleCare coupons bring the cash price down to $8 to $15 per pack.
• No manufacturer assistance program: Aurobindo Pharma does not currently offer a savings card or patient assistance program for Aurovela Fe 1/20.

For patients with cost concerns, direct them to our provider's guide to helping patients save money on Aurovela Fe 1/20.

Tools and Resources for Your Practice

Several tools can help you and your patients navigate availability issues efficiently:

Medfinder for Providers

Medfinder is a pharmacy availability tool that shows real-time stock information for medications at pharmacies nationwide. You or your staff can use it to:

• Check which pharmacies near a patient have Aurovela Fe 1/20 in stock
• Identify pharmacies carrying equivalent generics
• Direct patients to specific pharmacies where they can fill their prescription

Consider integrating a quick Medfinder check into your workflow when patients report fill difficulties. Visit medfinder.com/providers for the provider-facing tools.

Equivalent Generics Reference

The following are all FDA-rated therapeutically equivalent (AB-rated) to Aurovela Fe 1/20:

• Junel Fe 1/20 (Teva Pharmaceuticals)
• Microgestin Fe 1/20 (Mayne Pharma)
• Blisovi Fe 1/20 (Lupin Pharmaceuticals)
• Larin Fe 1/20 (Novitium Pharma)
• Gildess Fe 1/20 (Teva Pharmaceuticals)

All contain norethindrone acetate 1 mg, ethinyl estradiol 20 mcg, and ferrous fumarate 75 mg in the same 21+7 configuration.

Looking Ahead

The Aurovela Fe 1/20 availability situation is unlikely to resolve completely in the near term, as it is driven primarily by pharmacy formulary decisions rather than manufacturing shortages. Providers should anticipate ongoing intermittent access issues and have a proactive plan in place:

1. Educate patients about generic equivalence during the initial prescribing visit
2. Write flexible prescriptions that allow generic substitution
3. Recommend Medfinder as a first step when patients report fill difficulties
4. Consider 90-day prescriptions to reduce refill frequency and associated disruptions
5. Document patient preferences in the chart to streamline future conversations

For patient-facing information, you can also direct patients to our articles on finding Aurovela Fe 1/20 in stock and alternatives to Aurovela Fe 1/20.

Final Thoughts

Aurovela Fe 1/20 remains a safe, effective, and affordable oral contraceptive. The availability challenges are real but navigable — and with the right tools and prescribing practices, providers can help ensure their patients maintain uninterrupted contraceptive coverage.

The key takeaway: this is a distribution and formulary issue, not a safety or manufacturing issue. With proactive prescribing, patient education, and tools like Medfinder, you can minimize disruptions for your patients.